UAE ends National Disinfection Programme

By Eudore R.Chand

Under-12 allowed to enter malls, restaurants

ABU DHABI 25 June 2020: The United Arab Emirates yesterday announced the completion of the National Disinfection Programme, effective Wednesday.

Dr Saif Dhaheri, spokesperson of the National Emergency Crisis and Disaster Management Authority (NCEMA), announced the completion of the National Disinfection Programme nationwide.

“Children below 12 in age are now allowed to enter commercial centres and restaurants across the emirates,” he said.

“The National Disinfection Programe has completed the sterilization of all utilities nationwide, including means of public transport,” he said, adding that sterilisation of public and private establishments will continue to ensure public safety.

However, public gatherings will remain prohibited, he said, calling for avoiding family visits, maintaining social distancing norms, and wearing masks and gloves when leaving home.

“It is compulsory to follow the three-passenger limit per vehicle if not from the same family. However, members of the same family are allowed to travel in the same vehicle,” he continued.

He warned against violating the preventive and precautionary measures affirming that legal action will be taken against any violators in order to ensure public safety.

450 new cases

Meanwhile, Amna Al Dahak Al Shamsi, official spokesperson of the UAE Government, said more than 44,291 additional Covid-19 tests were conducted, resulting in the detection of 450 new cases and taking the total number of infections in the country to 46,133.

She noted an additional 702 individuals have fully recovered from Covid-19, bringing the total number of recoveries to more than 34,405, adding that a total of 11,421 individuals are still being treated, most of whom are in stable condition.

She also announced the death of two individuals, taking the total number of fatalities in the country to 307.

CLICK FOR MORE NEWS ABOUT CORONAVIRUS

ALSO READ:

UAE launches world’s first covid phase III trial